RxDoctor Payments Data

Jeffrey Upton, MD

Urology · Carson City, NVNPI 1790744209

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 43.2% of the total. That places this record below the midpoint for urology clinicians in NV, where the typical reported total is $2,990.

$228in general payments, 2019–2025

Across 12 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$99
  • Sumitomo Pharma America, Inc.$39
  • Boston Scientific$38
  • Progenics Pharmaceuticals, Inc.$21
  • Blue Earth Diagnostics$17
  • Olympus America Inc.$14

What the payments were for

  • Food & beverage$228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$228 in reported general payments places this provider in the 15th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$421,545
Medicare patients
1,281
Services billed
6,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron230$153,809
MyrbetriqMirabegron156$110,477
Estradiol331$42,234
YuvafemEstradiol212$23,944
Tamsulosin Hcl1,146$19,281
PremarinEstrogens, Conjugated23$12,352
Finasteride702$10,105
Potassium Citrate ErPotassium Citrate106$7,098
Testosterone34$5,387
Fesoterodine Fumarate ErFesoterodine Fumarate31$4,154
Alfuzosin Hcl ErAlfuzosin Hcl148$3,247
Dutasteride84$2,919
Testosterone Cypionate37$2,424
Solifenacin Succinate80$2,393
Oxybutynin Chloride ErOxybutynin Chloride48$2,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$39$153,809230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 63 urology providers in Nevada.

Other urology in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →